Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ReinforceBG

Financiado

Interrogating basal ganglia reinforcement with deep brain stimulation in Parkins...

Interrogating basal ganglia reinforcement with deep brain stimulation in Parkinson’s disease. Dopamine and the basal ganglia have been conserved over more than 500 million years of evolution. They are fundamental to animal and human behaviour. Parkinson’s disease (PD) is associated with loss of dopaminergic innervation to... ver más

29/02/2028

CHARITE UNIVERSIT...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-25

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

CHARITE UNIVERSITAETSMEDIZI...

1.50M€ | Lider

Proyectos interesantes

PID2021-127034OA-I00 ESTUDIO DE LAS DINAMICAS NEURALES Y CONDUCTUALES ASOCIADAS A... 103K€ Cerrado

PID2021-128623OB-I00 ACTIVIDAD Y EXCITABILIDAD DE LA CORTEZA MOTORA EN LA ENFERME... 339K€ Cerrado

PID2020-113222RB-C21 DESARROLLO Y VALIDACION CLINICA DE UNA PLATAFORMA DE DETECCI... 125K€ Cerrado

RTI2018-101294-A-I00 CARACTERIZACION DE REDES CEREBRALES CON ESPECIFICIDAD CELULA... 34K€ Cerrado

EIN2020-112391 AUTOMATIZACION DE TERAPIAS AVANZADAS PARA PARKINSON 15K€ Cerrado

CNS2023-144790 Psicología 200K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 61 meses Fecha Inicio: 2023-01-25
Fecha Fin: 2028-02-29

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Dopamine and the basal ganglia have been conserved over more than 500 million years of evolution. They are fundamental to animal and human behaviour. Parkinson’s disease (PD) is associated with loss of dopaminergic innervation to the basal ganglia. Over 6 million people suffer from the debilitating symptoms of PD that span disturbance of emotion, cognition and movement. There is a pressing need to understand the pathogenesis of these symptoms, but an integrated account of dopamine and basal ganglia function is lacking. This constitutes a significant roadblock to scientific and therapeutic advances. To overcome this roadblock, ReinforceBG poses the novel unconventional hypothesis that loss of dopamine in PD does not impair movement per se but leads to chronic negative reinforcement of neural population dynamics. Conversely, in the healthy state, transient dopamine signals may stabilize cortex–basal ganglia activity to facilitate reentry and refinement of cortical output. To address this hypothesis, ReinforceBG will combine invasive electrocorticography and local field potential recordings with closed-loop deep brain stimulation in PD patients. Aim 1 will investigate how basal ganglia pathways coordinate neuromuscular adaptation. Aim 2 will shed light on basal ganglia reinforcement in multiple behavioural domains, including movement, gait, speech, and spatial navigation in virtual reality. Aim 3 will develop a neuroprosthetic brain-computer interface that aims to modulate basal ganglia reinforcement. ReinforceBG deviates from outdated models on pro- vs. antikinetic Go and NoGo pathways and promises a holistic-reinforcement centred view of basal ganglia function. It will leverage the unprecedented spatiotemporal precision of neuromodulation for the development of an innovative brain circuit intervention that modulates neural reinforcement in real time. This opens new horizons for the interdisciplinary treatment of brain disorders affecting the dopaminergic system.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores